Browsing Tag
Teva Pharmaceutical Industries Ltd.
4 posts
Why support-platform strategy may become a differentiator in schizophrenia treatment markets
See why Teva Pharmaceutical Industries Ltd.’s support-platform strategy could reshape schizophrenia treatment markets and competitive positioning. Read more.
Why Teva’s once-monthly olanzapine shot could finally change how schizophrenia is treated in the U.S.
Find out how Teva’s FDA-accepted once-monthly olanzapine injection could reshape schizophrenia care and what investors and clinicians will watch next.
Teva’s new bipolar breakthrough: FDA clears UZEDY as the first monthly long-acting risperidone
Teva’s UZEDY long-acting injectable gains FDA approval for bipolar I maintenance, reshaping psychiatric treatment and investor sentiment.
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial,…